TABLE 4.

Prevalence of the MetS among various countries (by definition and by sex where data were provided)

	Ref.	n	Age (yr)	ATPIII 2001	WHO	IDF	EGIR
Australia	26	11,247 (8438 no DM)	≥25	24.4% m, 19.9% w	25.4% m, 18.2% w	34.4% m, 27.2% w	15.6% m, 11.3% w
Brazil	56	1,242	40–74	25.9% m, 40.9% w
Cameroon	99	1,573	24–742	0% m, 0% w	4.9% m, 2% w	0% m, 0% w
Canada (non-Aboriginal)	39	2,0581	18+	30.6% m, 29.2% w
Canada (Inuits)	39	2381	18+	6.7% m, 18.8% w
China	32	6,610	∼52	18.5% m, 15.7% w	18.1% m, 22.4% w	16.2% m, 19.0% w	11.8% m, 12.2% w
China	40	15,5401	35–74	9.8% m, 17.8% w
Denmark	29	2,4931	41–72	18.6% m, 14.3% w		23.8% m, 17.5% w
Finland	34	2,182	24–39	13.0% m/w		14.9% m/w	9.8% m/w
Finland	35	2,0491	45–64		38.8% m, 22% w
France	41	3,7701	30–64	11.0% m, 8.0% w
Greece	59	2,282	>18	25.2% m, 14.6% w
Greenland	36	9171	≥35	13% m, 22% w	20% m, 22% w
Hungary	27	13,3831	30–60	6.7% m, 9.8% w		14.9% m, 8.6% w
Southern India (Urban)	28	2,3501	20+2	17.1% m, 19.4% w	27.3% m, 19.7% w	23.1% m, 28.2% w
Northern India (Urban)	57	300	20+	18.4% m, 30.9% w
Iran	33	10,368	20+	24.0% m, 40.5% w	17.0% m, 20.0% w	21.0% m, 41.0% w
Ireland	42	8901	50–69	21.8% m, 21.5% w	24.6% m, 17.8% w
Italy	56	1,198	40–74	26.8% m, 23.7% w
Northern Jordan	43	1,1211	25–85	28.7% m, 0.9% w
Mexico	44	2,1581	20–69	28.5% m, 25.2% w	13.4% m, 13.8% w
Oman	45	1,4191	20–99	19.5% m, 23.0% w
Palestine	46	9921	30–65		17.0% m/w
Peru	47	1,8781	20–80	18.1% m/w
Philippines	48	4,5411	>20	14.3% m, 14.1% w
Russia	49	1461	25–89	66.9% m/w
Slovakia	50	6571	≥30		20.0% m/w
South Korea	51	40,6981	20–82	5.2% m, 9.0% w
Spain	30	2,540	35–64	22.0% m, 28.8% w		27.3% m, 31.7% w
Sweden	37	5,047	46–68	20.6% m/w		21.9% m/w	18.8% m/w
Sweden	24	1,007	45–69	14.8% m, 15.3% w
Sweden	38	508	70	26.3% m, 19.2% w
Tunisia	31	8631	40+	14.6% m, 30.8% w	25.7% m, 30.8% w	30.0% m, 55.8% w
Turkey	52	4,2591	20–90	28.0% m, 39.6% w
Turkey	58	2,296	28+	32.2% m, 45.0% w
Taiwan	55	5,936	20–80	18.3% m, 13.6% w		16.1% m, 13.3% w

DM, Diabetes mellitus; m, men; w, women.

¹T2D included.

²Not age-adjusted.